A Phase 2a, Randomised, Double Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-B thalassemia.

Administered By

Awarded By

Contributors

Start/End

  • November 12, 2019 - September 14, 2021